Guang Biao Zhou | Cancer immunology | Best Researcher Award

Published on by Global Academic Awards

Prof. Guang Biao Zhou | Cancer immunology | Best Researcher Award

Prof. Guang Biao Zhou, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

Prof. Guang-Biao Zhou is a renowned cancer biologist and Deputy Director of the State Key Laboratory of Molecular Oncology at the National Cancer Center, Chinese Academy of Medical Sciences. His research focuses on 🫁 environmental lung carcinogenesis and cancer therapeutics, exploring the roles of genomic changes and non-coding RNAs in pollution-induced lung cancer. He has identified key factors like AhR, CXCL13, and CDC34 in tobacco and air pollution-related cancer pathways. πŸ“š With over 150 peer-reviewed publications, Dr. Zhou also serves as Executive Deputy Editor-in-Chief of Frontiers of Medicine and CAE Transactions on Medicine.

Publication Profile

Scopus

Orcid

πŸŽ“ Education & Qualifications

Prof. Guang-Biao Zhou earned his MD and Ph.D. in Medicine from the prestigious School of Medicine at Shanghai Jiao Tong University, Shanghai, China πŸ›οΈ. His academic training spanned from August 25, 2000, to July 1, 2003, equipping him with a solid foundation in medical science and research 🧬. This rigorous education laid the groundwork for his future contributions to oncology, particularly in environmental lung carcinogenesis and therapeutic innovation 🫁. Prof. Zhou’s qualifications reflect both academic excellence and a strong commitment to advancing medical knowledge πŸ“š, shaping his path as a leading figure in cancer biology

πŸ’Ό Professional Experience

Prof. Guang-Biao Zhou has held esteemed positions across leading Chinese research institutions. Since October 2018, he has been serving as a Professor at the State Key Laboratory of Molecular Oncology, Cancer Hospital, Chinese Academy of Medical Sciences in Beijing πŸ₯. Prior to this, from 2009 to 2018, he was a Professor at the State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences 🧫. His earlier tenure from 2005 to 2009 was at the Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences 🧬, marking a strong trajectory in biomedical research leadership

Research Focus

Prof. Dr. Guang-Biao Zhou is a leading researcher in the fields of lung cancer biology 🫁, molecular oncology 🧬, and immunotherapy πŸ’‰. His work focuses on the molecular mechanisms of tumor progression, such as metabolic reprogramming, apoptosis, and immune regulation. He has contributed to high-impact studies involving non-small cell lung cancer, cancer vaccine development, PD-L2-mediated immune responses, and thalassemia treatments. His interdisciplinary approach bridges genomic regulation, mitochondrial-associated cell death, and drug resistance pathways, aiming to improve prognostic markers and therapeutic targets. Zhou’s research is frequently published in top-tier journals like Molecular Cell, Nature Biomedical Engineering, and Cell Discovery.

Conclusion

Prof. Guang-Biao Zhou is highly suitable for the Research for Best Researcher Award. His work not only advances scientific understanding but also offers practical implications for improving global health outcomes.Β 

Publication Top Notes

  • 🧬 Oncogenic functions and therapeutic potentials of targeted inhibition of SMARCAL1 in small cell lung cancer – Cancer Letters, 2024 | πŸ“… 2024 | DOI: 10.1016/j.canlet.2024.216929

  • ⚑ CIP2A induces PKM2 tetramer formation and oxidative phosphorylation in NSCLC – Cell Discovery, 2024 | πŸ“… 2024 | DOI: 10.1038/s41421-023-00633-0

  • πŸ§ͺ 10,11-Dehydrocurvularin attenuates inflammation via NLRP3 suppression – Chinese Journal of Natural Medicines, 2023 | πŸ“… 2023 | DOI: 10.1016/S1875-5364(23)60418-2

  • 🌫️🧬 Air pollution, EGFR mutation, and cancer initiation – Cell Reports Medicine, 2023 | πŸ“… 2023 | DOI: 10.1016/j.xcrm.2023.101046

  • 🌿✨ Corrigendum: Promising anticancer activities of Centipeda minima compounds – Phytomedicine, 2023 | πŸ“… 2023 | DOI: 10.1016/j.phymed.2022.154472

  • 🧠🧬 Alternative splicing of FAK in pancreatic and breast neuroendocrine tumors – Frontiers of Medicine, 2023 | πŸ“… 2023 | DOI: 10.1007/s11684-023-1009-7

  • πŸ›‘οΈπŸ§« CD47 in tumor immune evasion and targeted therapy – Journal of Sichuan Univ. (Med Sci), 2023 | πŸ“… 2023 | DOI: 10.12182/20230560101

  • πŸ§ͺ🧬 Nuclear AhR and membranous PD-L1 predict PD-1 response in NSCLC – Signal Transduction & Targeted Therapy, 2023 | πŸ“… 2023 | DOI: 10.1038/s41392-023-01416-5

  • πŸš¬πŸ›‘οΈ Tobacco carcinogen induces IDO1 and immune suppression – Signal Transduction & Targeted Therapy, 2022 | πŸ“… 2022 | DOI: 10.1038/s41392-022-01127-3

  • πŸ“’πŸ§¬ Correction: AhR mediates tobacco-induced PD-L1 and immunotherapy response – Nature Communications, 2022 | πŸ“… 2022 | DOI: 10.1038/s41467-022-30871-x

Xiang Yu | Regional Immunity | Best Researcher Award

Published on by Global Academic Awards

Prof. Xiang Yu | Regional Immunity | Best Researcher Award

Prof. Xiang Yu, Hainan University, China

Prof. Xiang Yu is a distinguished immunologist and professor at Hainan University’s School of Biomedical Engineering. He specializes in regional immunity, with a focus on liver immunity and immune visualization. Holding a PhD from Huazhong University of Science and Technology, he has significantly contributed to tumor immunology and nanomedicine. Prof. Yu has published over 59 SCI-indexed papers, including highly cited works in Nature Communications and ACS Nano. His research innovations, including nanovaccines and biomimetic probes, have garnered international recognition. He has supervised numerous doctoral students and received multiple awards, including the Young Scholar Award from the Chinese Society of Immunology.

Publication Profile

Scopus

Orcid

Education πŸŽ“πŸ“–

Prof. Xiang Yu obtained a Bachelor’s degree in Clinical Medicine from Wuhan University of Science and Technology in 2013. He later pursued a PhD in Biomedical Engineering at Huazhong University of Science and Technology, graduating in 2019. His doctoral research focused on immune microenvironment regulation, leading to groundbreaking findings in immune visualization and nanomedicine. During his academic journey, he developed expertise in tumor immunology, bio-nanotechnology, and immunotherapeutics. His education laid the foundation for his pioneering work in targeted liver immunity and innovative vaccine designs.

Experience πŸ«πŸ”¬

Since 2019, Prof. Xiang Yu has been a professor of immunology at Hainan University, mentoring graduate students and leading cutting-edge research projects. His expertise in immune-targeted therapies has driven advancements in biomedical imaging and tumor vaccines. Over the years, he has published over 59 high-impact journal articles, collaborated on international research projects, and contributed to multiple patents. He also holds editorial roles in prestigious journals, serves as a reviewer for SCI-indexed publications, and has been an invited speaker at global immunology conferences.

Awards and Honors πŸ†πŸŽ–

Prof. Yu has received four major awards, including the Young Scholar Award from the Chinese Society of Immunology. His groundbreaking research has been recognized with the Annual Best Paper Award by Journal of Nanobiotechnology. He has also earned two ESI Highly Cited Paper awards, highlighting his significant impact in immunology and nanomedicine. His students have won national and municipal prizes in academic competitions under his mentorship.

Research Focus πŸ”¬πŸ§¬

Prof. Xiang Yu’s research revolves around regional immunity, particularly liver immunity and immune visualization. His work includes bee venom-based liver endothelial targeting, whole-tumor-cell nanovaccines, and biomimetic probes for inflammatory diseases. His studies have led to novel immune regulation strategies for cancer metastasis and autoimmune disorders. His interdisciplinary approach combines bioengineering, nanotechnology, and immunology to develop innovative diagnostic and therapeutic solutions.

Publication Top Notes

  • Immune modulation of liver sinusoidal endothelial cells by melittin nanoparticles suppresses liver metastasis (Nature Communications, 2019)

  • Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response (Nature Communications, 2020)

  • Metastatic status of sentinel lymph nodes in breast cancer determined with photoacoustic microscopy via dual-targeting nanoparticles (Light: Science & Applications, 2020)

  • Biomimetic nanoplatform with selectively positioned indocyanine green for accurate sentinel lymph node imaging (Nanoscale, 2023)

  • Aptamer-modified melittin micelles efficiently inhibit osteosarcoma deterioration by inducing immunogenic cell death (Colloids and Surfaces B: Biointerfaces, 2025)

  • Breaking CHIPS-Mediated immune evasion with tripterin to promote neutrophil chemotaxis against MRSA infection (International Immunopharmacology, 2024)

  • Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Monobenzone-Induced Vitiligo in Mice (International Journal of Molecular Sciences, 2024)

  • Mitochondrial stress response in drug-induced liver injury (Molecular Biology Reports, 2021)

  • Hematoxylin and eosin staining of intact tissues via delipidation and ultrasound (Scientific Reports, 2018)